US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ODDITY Tech Ltd.

72.28

-1.7150-2.32%

Post-market: 72.280.00000.00%17:54 EDT

Volume:858.72K

Turnover:62.11M

Market Cap:4.03B

PE:41.61

High:73.86

Open:72.50

Low:71.08

Close:73.99

Loading ...

Overview Company News Filings

Oddity Tech Ltd. (ODD) Acquires Fionic1’s AI Technology to Enhance AI-Driven Beauty and Wellness Solutions

Oddity Tech Acquires Fionic's Tech Intellectual Property

MT Newswires Live

BRIEF-Oddity Acquires Intellectual Property And Elite Ai Research Team

Oddity Acquires Intellectual Property and Elite AI Research Team to Accelerate AI Capabilities

THOMSON REUTERS

ODDITY Acquires Intellectual Property and Elite AI Research Team to Accelerate AI Capabilities

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

ODDITY Tech Is Maintained at Overweight by Keybanc

SELLAS Announces Key Business Objectives for 2025

KeyBanc Raises Price Target on ODDITY Tech to $52 From $50, Keeps Overweight Rating

MT Newswires Live

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Nvidia, Netflix, TSMC New To These IBD Lists: Check Out Names On IBD 50, Stock Spotlight And More

Cboe Global Markets Reports Trading Volume for December and Full Year 2024

ODDITY Rises 6.7% in 3 Months: How Should You Play the Stock?

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Zacks.com featured highlights include DXP Enterprises, Ubiquiti, Sezzle and Oddity Tech

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

4 Top-Ranked Liquid Stocks to Enhance Portfolio Returns in 2025

JCR Pharmaceuticals' JR-441 Receives Orphan Drug Designation in Japan

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ODD/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":72.275,"timestamp":1749844800000,"preClose":73.99,"halted":0,"volume":858719,"hourTrading":{"tag":"盘后","latestPrice":72.275,"preClose":72.275,"latestTime":"17:54 EDT","volume":34660,"amount":2505027.195,"timestamp":1749851648341},"delay":0,"floatShares":38704922,"shares":55828291,"eps":1.736982,"marketStatus":"Not Yet Opened","change":-1.715,"latestTime":"06-13 16:00:00 EDT","open":72.5,"high":73.86,"low":71.0801,"amount":62108509.002670005,"amplitude":0.037571,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.736982,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":0,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":73.99,"preHourTrading":{"tag":"盘前","latestPrice":72,"preClose":73.99,"latestTime":"09:29 EDT","volume":2335,"amount":167094.86495,"timestamp":1749821395076},"postHourTrading":{"tag":"盘后","latestPrice":72.275,"preClose":72.275,"latestTime":"17:54 EDT","volume":34660,"amount":2505027.195,"timestamp":1749851648341},"volumeRatio":0.43898084332611054,"impliedVol":0.6025,"impliedVolPercentile":0.44},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":38704922,"roa":"14.35%","roe":"32.25%","lyrEps":1.769608,"volumeRatio":0.43898084332611054,"shares":55828291,"dividePrice":0,"high":73.86,"amplitude":0.037571,"preClose":73.99,"low":71.0801,"week52Low":32.71,"pbRate":"12.24","psRate":"5.74","week52High":79.1804,"institutionHeld":0,"latestPrice":72.275,"eps":1.736982,"divideRate":0,"volume":858719,"delay":0,"ttmEps":1.736982,"open":72.5,"prevYearClose":42.02,"prevWeekClose":77.35,"prevMonthClose":74.43,"prevQuarterClose":43.26,"fiveDayClose":77.35,"twentyDayClose":63.25,"sixtyDayClose":43.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2505479692","title":"Oddity Tech Ltd. (ODD) Acquires Fionic1’s AI Technology to Enhance AI-Driven Beauty and Wellness Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2505479692","media":"Insider Monkey","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505479692?lang=en_us&edition=fundamental","pubTime":"2025-01-22 15:29","pubTimestamp":1737530948,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 AI News You Should Not Miss.In this article, we are going to take a look at where Oddity Tech Ltd.  stands against the other AI stocks.Insights on AI's Potential and Its Evolving Capabilities. AI is rapidly advancing, with significant strides being made toward achieving more powerful and capable systems. While challenges and limitations have arisen along the way, the field is still evolving and finding innovative solutions to overcome obstacles. As AI systems grow increasingly capable, they are expected to perform tasks with human-level proficiency which can create new opportunities for efficiency and problem-solving.In an interview with CNBC, Dario Amodei, co-founder and CEO of Anthropic, discussed the ongoing developments in AI and emphasized that while past challenges have seemed like barriers, they were often overcome through innovations. He expressed confidence that AI is on track to achieve powerful capabilities in the next few years.For this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oddity-tech-ltd-odd-acquires-072908511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","QID","ODD","TSYW.SI","NVIW.SI","NQmain",".IXIC","TQQQ","SQQQ","BK4183","USJW.SI","USAW.SI","PSQ","QLD"],"gpt_icon":1},{"id":"2505020397","title":"Oddity Tech Acquires Fionic's Tech Intellectual Property","url":"https://stock-news.laohu8.com/highlight/detail?id=2505020397","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505020397?lang=en_us&edition=fundamental","pubTime":"2025-01-22 00:12","pubTimestamp":1737475926,"startTime":"0","endTime":"0","summary":"Oddity Tech  said Tuesday it has acquired fintech company Fionic's tech intellectual property.The company said Fionic's artificial intelligence research and development team, including co-founder Asaf Nurick and key members, have also joined Oddity.Financial details weren't disclosed.The transaction is not expected to significantly affect Oddity's financial position, cash flow, or earnings outlook for 2025, the company said.Price: 44.94, Change: +0.07, Percent Change: +0.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4183","CFA.SI","ODD"],"gpt_icon":0},{"id":"2505723278","title":"BRIEF-Oddity Acquires Intellectual Property And Elite Ai Research Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2505723278","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505723278?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:42","pubTimestamp":1737466929,"startTime":"0","endTime":"0","summary":"Jan 21 (Reuters) - Oddity Tech Ltd   :   * ODDITY ACQUIRES INTELLECTUAL PROPERTY AND ELITE AI RESEARCH TEAM TO ACCELERATE AI CAPABILITIESSource text:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","ODD","TISI","BK4183","AAQC"],"gpt_icon":0},{"id":"2505722732","title":"Oddity Acquires Intellectual Property and Elite AI Research Team to Accelerate AI Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2505722732","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505722732?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:00","pubTimestamp":1737464403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUA2BTFCJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ODD"],"gpt_icon":0},{"id":"2505209232","title":"ODDITY Acquires Intellectual Property and Elite AI Research Team to Accelerate AI Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2505209232","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505209232?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:00","pubTimestamp":1737464400,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  21, 2025  (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it has acquired the tech intellectual property of Fionic1, a fintech company with advanced AI modeling","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/21/3012585/0/en/ODDITY-Acquires-Intellectual-Property-and-Elite-AI-Research-Team-to-Accelerate-AI-Capabilities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TISI","BK4183","AAQC","BK4120","ODD"],"gpt_icon":0},{"id":"2502048757","title":"Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502048757","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502048757?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:44","pubTimestamp":1736430240,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., January 09, 2025----Cadrenal Therapeutics, Inc., , today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist  in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.Cadrenal Therapeutics, Inc. is a biopharmaceutical company in advanced clinical development focused on developing tecarfarin, a novel oral and reversible anticoagulant for the prevention of heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions.Tecarfarin is a vitamin K antagonist  potentially representing the first new therapeu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cadrenal-therapeutics-participate-lytham-partners-134400127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4183","CVKD","BK4211","SMMF","ODD","BK4137","BK4139","BK4007","HCSG"],"gpt_icon":0},{"id":"2502885590","title":"ODDITY Tech Is Maintained at Overweight by Keybanc","url":"https://stock-news.laohu8.com/highlight/detail?id=2502885590","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502885590?lang=en_us&edition=fundamental","pubTime":"2025-01-09 04:53","pubTimestamp":1736369580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 15:53 ET (20:53 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2501772285","title":"SELLAS Announces Key Business Objectives for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501772285","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501772285?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:20","pubTimestamp":1736342400,"startTime":"0","endTime":"0","summary":"- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Exp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006252/0/en/SELLAS-Announces-Key-Business-Objectives-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4202","BK4588","ALL","BK4109","BK4533","ODD","BK4183","BK4218","INN","BK4107","LU2355687059.USD","ASH","BK4585","BK4181","NCI","BK4139","LU1699723380.USD","LU2463526074.USD","LU0985320562.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2501662726","title":"KeyBanc Raises Price Target on ODDITY Tech to $52 From $50, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2501662726","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501662726?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:27","pubTimestamp":1736339273,"startTime":"0","endTime":"0","summary":"ODDITY Tech (ODD) has an average rating of overweight and mean price target of $52.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODD"],"gpt_icon":0},{"id":"2501444200","title":"Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2501444200","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501444200?lang=en_us&edition=fundamental","pubTime":"2025-01-07 22:34","pubTimestamp":1736260440,"startTime":"0","endTime":"0","summary":"Successfully dosed 6 patients in safety run-in segment, now accelerating enrollment. Positive data from first four patients announced December 2024. NXC-201 is the only one-time CAR-T therapy in development for AL Amyloidosis. NEXICART-2 is an open-label study designed to evaluate NXC-201 in patients with R/R AL Amyloidosis. The study has two segments: a six-patient “safety run-in” segment and a 34-patient dose expansion segment. The Phase 1b “safety run-in” segment dosed three patients at 150 million CAR-T cells and three patients at 450 million CAR-T cells . All six patients successfully completed a post-dosing safety evaluation, and enrollment can now proceed across U.S. study sites at 450 million CAR-T cells.NXC-201 is the only CAR-T therapy currently in development in AL Amyloidosis, mentioned in a review article entitled “Systemic Light Chain Amyloidosis” published in June, 2024 New England Journal of Medicine .About NXC-201 NXC-201 is a sterically-optimized BCMA-targeted chimeri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-accelerates-enrollment-u-143400342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","IE00B19Z4B17.USD","BK4230","CAR","BK4572","IE0034390439.USD","IE00B19Z6F94.USD","LU2065731478.USD","IMMX","CRS","BK4183","NXC","IE00B66KJ199.SGD","BK4104","BK4022","AL","BK4139","ODD","IE00B7SZL793.SGD","BK4006"],"gpt_icon":0},{"id":"2501200407","title":"MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2501200407","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501200407?lang=en_us&edition=fundamental","pubTime":"2025-01-07 22:12","pubTimestamp":1736259120,"startTime":"0","endTime":"0","summary":"Phase 2 pivotal trials to evaluate efficacy of THIO in combination with BeiGene’s checkpoint inhibitor  tislelizumab. CHICAGO, January 07, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply agreement with global oncology company BeiGene to assess the efficacy of THIO, its small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor  tislelizumab in three cancer indications. The single arm pivotal Phase 2 trials will study the drug combination in hepatocellular carcinoma , small cell lung cancer  and colorectal cancer .MAIA's preclinical results in HCC, with THIO in combination with a CPI, showed complete, durable and highly potent anti-tumor immune response. Preclinical results of THIO treatment in SCLC showed profound activation of innate and adaptive anti-tumor responses. In CRC pre-clinical studies, T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-clinical-supply-141200167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","CRC","BK4139","ODD","BK4006","BK4107","BK4585","LU0456854461.SGD","LU0266512127.USD","CPI","MAIA","L","BK4213","LBRJ","LU0053666078.USD","HCC","BK4588"],"gpt_icon":0},{"id":"2501020662","title":"Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism","url":"https://stock-news.laohu8.com/highlight/detail?id=2501020662","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501020662?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005336/0/en/Rezolute-Receives-Breakthrough-Therapy-Designation-from-FDA-for-Ersodetug-in-the-Treatment-of-Hypoglycemia-Due-to-Congenital-Hyperinsulinism.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HI","LU0029874061.USD","ODD","BK4183","LU0128526141.USD","BK4161","LU2360032135.SGD","LU2125154935.USD","LU2125154778.USD"],"gpt_icon":0},{"id":"2501050226","title":"Nvidia, Netflix, TSMC New To These IBD Lists: Check Out Names On IBD 50, Stock Spotlight And More","url":"https://stock-news.laohu8.com/highlight/detail?id=2501050226","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501050226?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:07","pubTimestamp":1736208421,"startTime":"0","endTime":"0","summary":"See which stocks like Nvidia have just been added to – or removed from – IBD’s stock lists, including the IBD 50, Sector Leaders, IBD Big Cap 20 and IPO Leaders.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate2-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate2-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/check-out-names-on-ibd-50-stock-spotlight-and-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["NVDS.UK","LU1066051811.HKD","LU1699723380.USD","ODD","NVDX","LU0109391861.USD","LU0868494708.USD","LU2077746001.SGD","LU2294711713.HKD","2NVD.UK","BK4549","NVDS","IE0034235303.USD","LU0889565833.HKD","LU0127658192.USD","LU0256863902.USD","LU1814569148.SGD","SG9999001424.SGD","LU2213496289.HKD","LU0882574139.USD","IE00BDCRKT87.USD","LU1496350502.SGD","NVIW.SI","NVDD","NVDU","LU2326559502.SGD","3NVD.UK","NVD3.UK","VIST","LU0572940350.SGD","LU0689472784.USD","LU0689626769.HKD","SNVD.UK","NVD","03145","NVD2.UK","SGXZ51526630.SGD","NVDA","LU1989772923.USD","NVDY","TSM","IBD","IE00BK4W5M84.HKD","LU1211504680.USD","LU0979878070.USD","LU2237443978.SGD","NFLX","LU0541502299.USD"],"gpt_icon":0},{"id":"2501381295","title":"Cboe Global Markets Reports Trading Volume for December and Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2501381295","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501381295?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:31","pubTimestamp":1736199060,"startTime":"0","endTime":"0","summary":"CHICAGO, Jan. 6, 2025 /PRNewswire/ -- Cboe Global Markets, Inc. , the world's leading derivatives and securities exchange network, today reported December and full year 2024 trading volume statistics across its global business lines and provided guidance for selected revenue per contract/net revenue capture metrics for the fourth quarter of 2024.The data sheet \"Cboe Global Markets Monthly Volume & RPC/Net Revenue Capture Report\" contains an overview of certain December and full year 2024 trading statistics and market share by business segment, volume in select index products, and RPC/net capture, which is reported on a one-month lag, across business lines.December and Full Year 2024 Trading Volume Highlights. Total volume across Cboe's four options exchanges was 3.8 billion contracts in 2024, with an ADV of 14.95 million contracts traded, the fifth consecutive record-breaking year.Overall proprietary index options product suite traded a total of 1.03 billion contracts, with an ADV of 4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cboe-global-markets-reports-trading-213100669.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cboe-global-markets-reports-trading-213100669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4532","ADV","BK4183","BK4112","BK4588","BK4009","ODD","CBOE"],"gpt_icon":0},{"id":"2501256948","title":"ODDITY Rises 6.7% in 3 Months: How Should You Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501256948","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501256948?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:28","pubTimestamp":1736170080,"startTime":"0","endTime":"0","summary":"ODDITY ODD shares have gained 6.7% in the past three months, underperforming the Zacks Internet - Software industry and Zacks Computer and Technology sector’s return of 8.5% and 8.4%, respectively.Although ODDITY has underperformed its industry and the broader tech sector, the company is scaling its business with a strong direct-to-consumer model and personalized products. ODDITY’s brands like IL MAKIAGE and SpoiledChild are also showing strong double-digit growth, reflecting ODD’s robust competence.ODDITY’s successful business model is reflected in its revenue growth. In 2023, ODD achieved $508.7 million in net revenues, up 56.7% from $324.5 million in 2022 and 45.8% from $222.6 million in 2021. ODDITY expects its 2024 revenues in the range of $642-$644. The Zacks Consensus Estimate for the same is pegged at $643 billion, indicating year-over-year growt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oddity-rises-6-7-3-132800125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002270589.USD","LU0690374615.EUR","LU0690374961.EUR","LU0124676726.USD","BK4588","ULVR.UK","BK4548","LU0689626769.HKD","BK4592","IE00B7SZLL34.SGD","BK4183","IE00B19Z3581.USD","COTY","LU2552382058.USD","BK4533","LU2404859667.USD","LU2404859741.USD","IE00B19Z3B42.SGD","UN","BK4558","BK4585","EL","ODD","UL","BK4504","LU2552382132.HKD","LU2552382215.SGD"],"gpt_icon":0},{"id":"2501239216","title":"Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239216","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239216?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Jan.  06, 2025  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3004535/0/en/Tempest-Receives-Orphan-Drug-Designation-from-the-U-S-Food-and-Drug-Administration-for-Amezalpat-to-Treat-Patients-with-Hepatocellular-Carcinoma-HCC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","BK4225","BK4183","ALD","OS","HCC","BK4006","HR","BK4097","ODD"],"gpt_icon":0},{"id":"2500917996","title":"Zacks.com featured highlights include DXP Enterprises, Ubiquiti, Sezzle and Oddity Tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2500917996","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500917996?lang=en_us&edition=fundamental","pubTime":"2025-01-02 15:15","pubTimestamp":1735802100,"startTime":"0","endTime":"0","summary":"Chicago, IL – January 2, 2025 – Stocks in this week’s article are DXP Enterprises, Inc. DXPE, Ubiquiti Inc. UI, Sezzle Inc. SEZL and Oddity Tech Ltd. ODD.4 Top-Ranked Liquid Stocks to Enhance Portfolio Returns in 2025. Liquidity of a stock is an important parameter that investors should consider while adding stocks to their investment portfolio. Liquidity primarily determines a company’s capability to meet debt obligations by converting assets into liquid cash and equivalents. These stocks are always in demand owing to their potential to provide maximum returns.Investors can consider adding these four top-ranked stocks like DXP Enterprises, Inc., Ubiquiti Inc., Sezzle Inc. and Oddity Tech Ltd. to their portfolios to boost returns.However, one should be alert enough before investing in such stocks. While a high liquidity level may imply that the company is clearing its dues faster than peers, it may also indicate that it is failing to use its assets efficiently.Management raised the top","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-dxp-071500006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","ODD","BK4227","SEZL","UI","BK4183","BK4104","BK4020","DXPE"],"gpt_icon":0},{"id":"2495186216","title":"Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2495186216","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495186216?lang=en_us&edition=fundamental","pubTime":"2024-12-31 21:00","pubTimestamp":1735650000,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., December 31, 2024----Cadrenal Therapeutics, Inc.  today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic anticoagulant therapy for warfarin-dependent patients with implanted cardiac devices including left ventricular assist devices  or for those with rare cardiovascular conditions.\"This year has marked significant opportunities and advancements for Cadrenal Therapeutics, with a strong focus on clinical indications,\" said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. \"The Company has established a targeted plan to advance the clinical development of tecarfarin and, if approved, to commercialize it as a significant improvement for LVAD patients facing challenges with chronic anticoagulation treatments. We look ahead to 2025 and the initiation of the pivotal Phase 3 clinical trial for tecarfarin in LVAD and developing this much-needed therapeut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cadrenal-therapeutics-provides-2024-end-130000663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","ODD","CSII","CVKD","LENZ","BK4139","CDMO","BK4007","BK4082"],"gpt_icon":0},{"id":"2495114556","title":"4 Top-Ranked Liquid Stocks to Enhance Portfolio Returns in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2495114556","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495114556?lang=en_us&edition=fundamental","pubTime":"2024-12-31 20:41","pubTimestamp":1735648860,"startTime":"0","endTime":"0","summary":"Liquidity of a stock is an important parameter that investors should consider while adding stocks to their investment portfolio. Liquidity primarily determines a company’s capability to meet debt obligations by converting assets into liquid cash and equivalents. These stocks are always in demand owing to their potential to provide maximum returns.Investors can consider adding these four top-ranked stocks like DXP Enterprises, Inc. DXPE, Ubiquiti Inc. UI, Sezzle Inc. SEZL and Oddity Tech Ltd. ODD to their portfolios to boost returns.However, one should be alert enough before investing in such stocks. While a high liquidity level may imply that the company is clearing its dues faster than peers, it may also indicate that it is failing to use its assets efficiently.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-top-ranked-liquid-stocks-124100229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ODD","BK4104","BK4532","BK4183","BK4227","SEZL","UI","BK4020","DXPE"],"gpt_icon":0},{"id":"2495555868","title":"JCR Pharmaceuticals' JR-441 Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2495555868","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495555868?lang=en_us&edition=fundamental","pubTime":"2024-12-30 07:41","pubTimestamp":1735515683,"startTime":"0","endTime":"0","summary":"JCR Pharmaceuticals Co (TYO:4552) has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for JR-441, an investigational drug for treating mucopolysacchar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4183","ODD"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":162,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-29","symbol":"ODD","fiscalQuarterEnding":"2025/03","expectedEps":0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"post","actualEps":0.63},{"market":"US","date":"2025-02-25","symbol":"ODD","fiscalQuarterEnding":"2024/12","expectedEps":0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"post","actualEps":0.06},{"market":"US","date":"2024-11-06","symbol":"ODD","fiscalQuarterEnding":"2024/09","expectedEps":0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":0.29},{"market":"US","date":"2024-08-07","symbol":"ODD","fiscalQuarterEnding":"2024/06","expectedEps":0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":0.71},{"market":"US","date":"2024-05-07","symbol":"ODD","fiscalQuarterEnding":"2024/03","expectedEps":0.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715054400000,"reportTimeType":"post","actualEps":0.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.5556,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1738382400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2025-06-13","current":38.84497,"percent":0.738758,"low":20.831575,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"high":144.174884,"avg":34.927998,"sd":17.317062,"marketCap":4130735251},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251}],"updateTime":1750024371468}}}